apatinib + chemoradiation

Apatinib + chemoradiation refers to the combination of the small molecule tyrosine kinase inhibitor apatinib with standard chemotherapy and radiotherapy regimens. Apatinib is an oral inhibitor that selectively targets vascular endothelial growth factor receptor-2 (VEGFR-2), thereby blocking angiogenesis and inhibiting tumor growth. When combined with chemotherapy or radiotherapy, this regimen aims to enhance anti-tumor efficacy by both direct cytotoxic effects (from chemo/radiation) and antiangiogenic mechanisms (from apatinib). This combination has been studied in several advanced cancers—including gastric cancer, lung adenocarcinoma, pancreatic cancer, breast cancer, and ovarian cancer—where it has shown improved progression-free survival and overall response rates compared to standard therapy alone. The safety profile is generally manageable; common adverse events include hypertension, proteinuria, hand-foot syndrome, fatigue, and hematologic toxicities[1][3][5][7].

Other names

apatinib mesylatechemoradiation